Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing,...read more
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to...read more
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion...read more
US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of...read more
Immuno-oncology biotech iTeos Therapeutics prices upsized IPO at $19, above the range
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing,...read more
Oncology biotech iTeos Therapeutics sets terms for $151 million IPO
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to...read more